COMPANY SUMMARY BIO Boston 1x1 meeting ABIVAX ___________ MISSION NAME OF THE CEO ABIVAX is a biotechnology company harnessing the immune system to develop a functional cure for HIV and treatments for inflammatory diseases and cancer. Prof Hartmut Ehrlich, M.D. TECHNOLOGY ABIVAX leverages three technology platforms for drug discovery: Pr • an antiviral platform • an immune enhancement platform Eh • a polyclonal antibody platform Ch ALLIANCES/PARTNERSHIPS Of Partnerships • CNRS / Curie Institute Licenses • Scripps Research Institute ADDRESS UPCOMING CATALYSTS 5 rue de la Baume, 75008 Paris key operational milestones Q1 2019 ___________________ Candidate Q2 2018 Q3 2018 Q4 2018 EMAIL ABX464 IND 1 FSI 2 Topline data info@abivax.com Filing 005-study Phase IIb HIV www.abivax.com ABX464 Topline data IND FSI 101-study Filing Phase IIb UC MANAGEMENT TEAM CEO: Prof. Hartmut Ehrlich, M.D. ABX196 IND FSI HCC- CFO: Didier Blondel HCC Filing Phase I/II CMO: Jean-Marc Steens, M.D. CCO & VP BD : Pierre Courteille MARKET FIGURES R evenues 2017: 0 € TARGETED Date of IPO: June 2015 MARKET Ticker: ABVX.PA Exchange: Euronext Paris ____________ Currency: € Market cap: 72 million € (as of May 3, 2018) • HIV: Towards a functional cure for Price: 7.33 € (as of May 3, 2018) HIV: Targeting RNA splicing 52-weeks-high: 18.76 € • IBD (Ulcerative Colitis & Crohn’s 52-weeks-low: 7 € Disease) Average daily volume: 52000 per day in 2017 • Immuno-oncology in HCC in KEY FIGURES combination with checkpoint inhibitors € m 2016 2017 Growth (%) Sales 0 0 0% LISTED COMPANY EBIT -18 -14 22% Net Income -14 -11 21% CREATION DATE Cash Position 17 23 -26% December 2013
COMPANY SUMMARY BIO Boston 1x1 meeting ABIVAX ___________ NAME OF THE CEO ANALYST COVERAGE Prof Hartmut Ehrlich, M.D. Broker Date Reco. Target Price Potential (%) Pr (buy/neutral/hold) NIBC 03/2018 Buy 15,10 € +106% Eh Goetz Partners 10/2017 Buy 19,50 € +166% RBC 05/2017 Buy 26,00 € +255% Ch Average: - Buy 20,2 € +176% Of SHAREHOLDERS ADDRESS Shareholder structure 2 (undiluted) 5 rue de la Baume, Public 75008 Paris 35% ___________________ EMAIL Truffle info@abivax.com Capital 60% www.abivax.com Incubator Holding Founders MANAGEMENT TEAM 3% 2% CEO: Prof. Hartmut Ehrlich, M.D. CFO: Didier Blondel As of December 31 st , 2017 CMO: Jean-Marc Steens, M.D. CCO & VP BD: Pierre Courteille PIPELINE TARGETED MARKET Lead generation ____________ Research Preclinical Phase 1 Phase 2 Phase 3 HIV In 3 rd Phase 2 ABX464 • Lasting viral remission HIV: Towards a functional cure for HIV: Targeting RNA splicing Ulcerative Colitis ABX464 In Phase 2 POC • IBD (Ulcerative Colitis & Crohn’s Anti-inflammatory Disease) • Cancer Clinical trial in Immuno-oncology in HCC in ABX196 HCC to start Q4 2018 Immune enhancer combination with checkpoint inhibitors Ebola ABX544 Polyclonal antibodies Dengue LISTED COMPANY Antiviral drug Respiratory Syncytial Virus CREATION DATE Antiviral drug December 2013 Influenza Antiviral drug
Recommend
More recommend